WebSince 2012, we have marketed Korlym® for the treatment of patients suffering from Cushing’s syndrome, a life-threatening orphan disorder caused by excess cortisol activity. In 2024, we generated revenue of $366 million and net income of $113 million. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Web10 apr. 2024 · And while Korlym’s annual costs pale against other specialty drugs, which run as high as $750,000 a year, the climbing price tag and increasing number of patients do …
Corcept Therapeutics Settles Patent Litigation with Hikma …
Web13 jul. 2024 · Korlym cannot be used in the treatment of patients with type 2 diabetes mellitus unrelated to endogenous Cushing’s syndrome (1). Korlym carries a boxed … Web1 mrt. 2024 · Mifepristone (Korlym®, Corcept Therapeutics), a glucocorticoid receptor (GR) antagonist, is FDA-approved for the treatment of hyperglycemia in patients with endogenous Cushing syndrome (CS). the communards - don\u0027t leave me this way song
SVB Leerink Initiates Coverage of Corcept Therapeutics (CORT) …
Web12 apr. 2024 · Cincinnati's Procter & Gamble is one of Ohio's largest companies in terms of revenue. In 2010, Ohio was ranked No. 2 in the country for best business climate by Site Selection mag WebList of Marketing Authorisations (MA) containing Korlym registered and approved in Europe on PharmaCompass.com WebSince 2012, we have marketed Korlym® for the treatment of patients suffering from Cushing’s syndrome, a life-threatening orphan disorder caused by excess cortisol activity. In 2024, we generated... the communards - don\\u0027t leave me this way song